Calliditas Therapeutics (Formerly known as Pharmalink)
85 articles with Calliditas Therapeutics (Formerly known as Pharmalink)
Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2021. The nomination committee, which is appointed in accordance with the principles adopted by the extraordinary general meeting on September 14, 2017 , consists of: · Patrick Sobocki, appointed by Stiftelsen Industrifonden
On August 13th, we announced a €19.8m acquisition of a majority stake of 62.7% in Genkyotex, a publicly listed life science company in France.
On November 12, 2020 , at 07:00 am CET , Calliditas Therapeutics ("Calliditas") will publish its business update for the third quarter 2020. Calliditas will also host a telephone conference, which will include a presentation of the results, on the same day at 2:30 pm CET . The event will be hosted by the company's CEO, Renée Aguiar-
Calliditas Therapeutics AB announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon® versus placebo in patients with primary IgA nephropathy.
Calliditas Therapeutics to host conference call on positive topline results from pivotal phase 3 NefIgArd trial
On November 8, 2020, Calliditas announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon® versus placebo in patients with primary IgA nephropathy.
Calliditas said Nefecon hit its primary endpoint by demonstrating a statistically significant reduction in urine protein creatinine ratio, UPCR or proteinuria, after nine months of treatment.
Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; NASDAQ - CALT) today announced the closing of the acquisition of 62.7% of Genkyotex SA ("Genkyotex") (Euronext Paris & Brussels: FR0013399474 - GKTX) in an off-market transaction. On August 13, 2020 , Calliditas announced that it had entered into an agreeme
Calliditas Therapeutics AB announced upcoming presentations concerning Nefecon, its lead product candidate, at the American Society of Nephrology Kidney Week 2020 Reimagined conference, to be held virtually October 19-25, 2020.
The 200th patient's last visit completed in Part A of NefIgArd supporting topline readout in pivotal Phase 3 trial in Q4, 2020
Calliditas Therapeutics AB announced that the last visit of the 200th patient has taken place in Part A of the pivotal NeflgArd Phase 3 study
During September, Calliditas Therapeutics AB has allotted 111,250 common shares within the company's warrant program issued in 2017.
Calliditas Therapeutics AB announced that the first patient in China has been randomized into confirmatory part of the NefIgArd Phase 3 trial by its partner, Everest Medicines.
Calliditas Therapeutics AB announced the appointment of Jonathan Schur as Group General Counsel, effective October 1, 2020.
"In June we successfully closed a $90m U.S. IPO on NASDAQ, which including the greenshoe that was exercised in July, resulted in gross proceeds of $97m in total.
Transaction adds late-stage orphan pipeline asset and platform in inflammation and fibrosis. Calliditas to acquire 62.7% of Genkyotex for €20.3M in cash at €2.80 per share in an off-market transaction.
During July, Calliditas Therapeutics AB has issued 706,676 common shares as a result of the exercise of the over-allotment option within the initial public offering on The Nasdaq Global Select Market and the concurrent private placement of common shares to certain qualified investors in Europe and certain other jurisdictions outside of the United States.
Calliditas Therapeutics AB announced that it has reorganized its management team.
Citigroup Global Markets Inc., in its capacity as Joint Global Coordinator, notifies that the stabilization period relating to Calliditas Therapeutics AB 's American Depositary Shares, traded on The Nasdaq Global Select Market has ended and no further stabilization transactions will be effected.
During June, Calliditas Therapeutics AB (publ) has issued 9,230,770 common shares as a result of the initial public offering on The Nasdaq Global Select Market in the United States and concurrent private placement of common shares to certain qualified investors in Europe and certain other jurisdictions outside of the United States.
Calliditas Therapeutics AB announced that its CEO Renée Aguiar-Lucander will exercise warrants granted pursuant to Calliditas' Warrant Program 2017/2020, which corresponds to an investment totaling SEK 15.7 million.
Calliditas Therapeutics Prices its Initial Public Offering on The Nasdaq Global Select Market in the United States
Calliditas Therapeutics AB announced the pricing of its initial public offering on The Nasdaq Global Select Market by way of a capital increase of 9,230,770 new common shares, consisting of a public offering of 8,306,770 common shares in the form of American Depositary Shares...